CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

11025	Companies
241656	Keywords
170132	Articles
130105	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 10 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 10 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 10 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 10 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 2 years ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 2 years ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 2 years ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 2 years ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 2 years ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 years ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 09/19/2026 at 00:55, 6 hours 22 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 7 hours 27 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 9 hours 17 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 10 hours 42 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 16 hours 47 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 12 hours 32 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 12 hours 33 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 13 hours 4 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 13 hours 7 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 13 hours 10 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 12 hours 43 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 13 hours 32 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 13 hours 32 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 13 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 10 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE